Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 21, 2009Journal of Medicinal ChemistryOpen Access

Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBrenton FlattExelixis (United States)RMRichard MartinPrimary HealthCareTWTielin WangJilin University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Flatt et al. (2009) studied this question.

synapsesocial.com/papers/6aaa177d43aa2451128440bbhttps://doi.org/10.1021/jm8014124
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FXR signaling in metabolic disease2007 · 209 citations
  2. 2Biomimetic syntheses of indole alkaloids. 11. Syntheses of .beta.-carboline and indoloazepine intermediates1985 · 39 citations
  3. 3Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors.1995 · 365 citations